xenia sheveleva melanotan 28th Annual ATHENA Leadership Award Luncheon Xenia Cherkaev - Bulletin of

Infection 42, 513

(3) Patient stratification: Leverage mechanistic differences between CHS and EHS to design tailored trialse.g., testing anti-pyroptotic/anti-necroptotic agents in EHS and anti-apoptotic/gut barrier protectants in CHS [60, 61]

Owing to their distinct biochemical mechanisms that suppress lipid peroxidation and reduce ROS production, these compounds have been investigated in clinical studies to assess the therapeutic value of their antioxidant properties (Table 1)

10.1007/s12035-017-0728-7 Mol

FM: Conceptualization, Funding acquisition, Supervision, Writing original draft, Writing review & editing